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Background. Since the identification of Zika virus (ZIKV) in Brazil in May 2015, the virus has spread throughout the Americas. 
However, ZIKV burden in the general population in affected countries remains unknown.
Methods. We conducted a general population survey in the different communities of French Guiana through individual inter-
views and serologic survey during June–October 2017. All serum samples were tested for anti-ZIKV immunoglobulin G antibodies 
using a recombinant antigen-based SGERPAxMap microsphere immunoassay, and some of them were further evaluated through 
anti-ZIKV microneutralization tests.
Results. The overall seroprevalence was estimated at 23.3% (95% confidence interval [CI], 20.9%–25.9%) among 2697 partici-
pants, varying from 0% to 45.6% according to municipalities. ZIKV circulated in a large majority of French Guiana but not in the 
most isolated forest areas. The proportion of reported symptomatic Zika infection was estimated at 25.5% (95% CI, 20.3%–31.4%) in 
individuals who tested positive for ZIKV.
Conclusions. This study described a large-scale representative ZIKV seroprevalence study in South America from the recent 
2015–2016 Zika epidemic. Our findings reveal that the majority of the population remains susceptible to ZIKV, which could poten-
tially allow future reintroductions of the virus.
Keywords. Zika virus; seroprevalence study; general population survey; French Guiana.
Zika virus (ZIKV) is a flavivirus transmitted by mosquitoes, 
primarily Aedes aegypti, which also transmits dengue, chikun-
gunya, and yellow fever viruses. It was first isolated in 1947 in 
African forests, where it circulates between nonhuman primates 
and sylvatic mosquitoes [1]. ZIKV was considered as an emer-
gent virus with few sporadic cases reported in Africa and Asia 
until 2007, when a major epidemic occurred in Yap, Federated 
States of Micronesia [2], followed by one in French Polynesia 
in 2013 [3, 4]. Subsequently, ZIKV continued to spread in the 
Pacific region [5] and emerged in South America in early 2015 
[6, 7]. During these recent outbreaks, the virus was linked to 
neurological disorders [8, 9], severe congenital abnormalities, 
and human birth defects [10–14], leading the World Health 
Organization to declare a Public Health Emergency of 
International Concern [15]. Several recent studies have also 
highlighted that ZIKV can be transmitted through sexual con-
tact or from mother to fetus [13, 16, 17]. In French Guiana, a 
French overseas department of 260 000 inhabitants that is lo-
cated in Latin America in the Amazonian forest complex, Ae. 
aegypti mosquitoes have been responsible for several major 
dengue fever outbreaks [18, 19] and for the chikungunya out-
break in 2014 [20, 21]. Given the risk of congenital complica-
tions, the emergence of ZIKV was particularly concerning for 
its inhabitants as the territory has the highest fertility rate in 
the Americas (3.5 children per woman) [22]. During the ZIKV 
epidemic in French Guiana (January–September 2016), ap-
proximately 9700 clinical cases (approximately 4% of the popu-
lation), with 14 congenital abnormalities including 3 instances 
of microcephaly, were recorded by local health authorities [23]. 
A territory-wide active monitoring of pregnant women imple-
mented during the first 4 months of the outbreak also showed 
that 573 of 3050 (19%) enrolled pregnant women had labora-
tory evidence of ZIKV infection [22]. However, the ZIKV infec-
tion burden remains unclear in the general population. In such 
a context, population-representative seroprevalence studies 
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provide an opportunity to estimate the underlying burden of in-
fection and to assess the potential for future epidemics of ZIKV 
in the region.
A number of seroprevalence studies have recently been con-
ducted in affected countries and territories in the Americas 
among specific subgroups of populations and geographical 
areas. ZIKV seroprevalence was found to be 63% in patient 
cohorts and university employees in Salvador, Brazil [24], 
73% in a cohort of individuals residing in Pau da Lima com-
munity in the Salvador [25]. In Bolivia, ZIKV seroprevalence 
was estimated in blood donors at 39% in Beni, 21.5% in Santa 
Cruz de la Sierra and close to 0% in three different highland 
regions (Cochachamba, La Paz and Tarija) [26]. In Managua, 
Nicaragua, ZIKV seroprevalence was estimated at 36%, 46%, 
and 56% among participants of pediatric, household, and adult 
cohort studies, respectively [27]. In Suriname, seroprevalence 
rates were estimated at 35.1% and 24.5% in patient cohorts re-
cruited from urban areas and 1 remote village, respectively [28]. 
In the Caribbean sea, ZIKV seroprevalence was estimated at 
42.2% in blood donors in Martinique island [29]. These studies 
were all performed in a small number of communities or spe-
cific population subgroups in a constrained region. It is unclear 
whether their findings are generalizable to the wider popula-
tion. No territory-wide study evaluating the impact of ZIKV 
emergence in the general population has yet been published. 
Such population-representative studies constitute the most re-
liable source of information and often estimate seroprevalence 
rates that are lower but more representative than those obtained 
in population subgroups [30, 31].
In this context, we conducted a cross-sectional study within 
the general population of French Guiana in the year following 
the end of the outbreak, to characterize the seroprevalence of 
ZIKV and assess its association with sociodemographic and ge-
ographical factors.
METHODS
Study Design and Participants
We conducted a cross-sectional population-based study through 
household interviews and serologic survey during June–October 
2017, involving residents located in the 22 municipalities of 
French Guiana. The territory is composed of 2 main inhabited 
geographical regions: a central urbanized and coastal strip area 
along the Atlantic Ocean (“coastal area”) where a large part of the 
population lives, and 4 distinct remote areas along the Surinamese 
and Brazilian frontiers (“interior area”) (Figure 1).
We estimated the sample size for this survey at 2500 persons 
distributed in the 5 delimited geographical areas based on a 
50% seroprevalence, 95% confidence, 90% power, and a cluster 
effect. To reach the desired sample size, a total of 1600 house-
holds were randomly selected for possible participation in the 
study from household databases maintained by the Geographic 
Information and Knowledge Dissemination Unit of the 
Regional Environment, the planning and housing agency, and 
the National Institute of Economic and Statistical Information. 
A  stratified simple random sampling method was adopted to 
select households from the 22 municipalities (strata), allowing 
an overrepresentation of isolated and small municipalities. 
Villages from 4 municipalities (Roura, Maripasoula, Regina, 
and Camopi) were specifically considered in the sample design 
to ensure that all existing submunicipality areas were adequately 
represented among the selected households. The distribution 
of households selected from the 22 strata is presented in Table 
1. The global sampling fraction of the households was 1:49, 
varying from 1:103 to 1:5 according to the municipality.
Procedures and Ethical Considerations
Publicity and information about the survey was provided through 
the media and contact with local and national authorities. 
Fieldworker teams including investigators and nurses or medicine 
residents were trained to visit all households, explain the project 
objectives, and, when allowed, collect participants’ signatures in a 
free and informed consent form and carry out the interviews. All 
members of selected households who were 2–75 years of age were 
invited to take part in the study during a preliminary face-to-face 
interview. For all participants <18 years of age, 1 or 2 responsible 
adults signed the informed consent form. A specific educational-
style comic book was designed for children 6–17 years of age to 
explain, in an understandable way, the nature and objectives of the 
survey and inform them about the voluntary nature of their par-
ticipation in the study and their rights to access and rectify their 
personal information (Supplementary Materials 1).
Data were collected through a standardized questionnaire 
installed on tablets to register demographics, socioeconomics, 
and household characteristics. Participants were asked to report 
the occurrence of a presumptive ZIKV infection, to report the 
year of Zika presumptive infection, to list the specific associ-
ated symptoms (open-ended question), and to specify if they 
had consulted a doctor or obtained a biological confirmation 
of their infection. Thereafter, a venous blood sample of 10 mL 
was collected from each participant, in accordance with current 
biosafety standards.
The study was recorded on ClinicalTrials.gov (NCT03210363) 
and approved by the Sud-Ouest & Outre-Mer IV Ethical 
Research Committee (number CPP17-007a/2017-A00514-49) 
and by the French Data Protection Authority (number 




Blood samples were collected into 5-mL gold BD Vacutainer 
SST II advance tubes with gel for serum separation (Becton-
Dickinson). Immediately after puncture, samples were stored at 
4°C–8°C until centrifugation within 12 hours. Sera were then 



























































































Figure 1. Map of French Guiana with geographical areas.
1918 • jid 2019:220 (15 december) • Flamand et al
frozen and stored at –20°C until use at the National Reference 
Center for arboviruses in Institut Pasteur in French Guiana.
Serologic Diagnosis
All serum samples were tested for anti-ZIKV immunoglob-
ulin G (IgG) antibodies using a recombinant antigen-based 
SGERPAxMap microsphere immunoassay (MIA) adapted from 
Beck et al [32]. ZIKV Luminex MIA uses the ZIKV E3 domain as 
the epitope rather than the whole E protein as in traditional ELISAs. 
The E3 domain has been shown to limit cross-reactivity between 
flaviviruses [33–38] (see Supplementary Materials and Methods). 
In such a way, this assay limits the probability that individuals pre-
viously infected with dengue falsely test as ZIKV positive.
Furthermore, some of the samples were evaluated through 
anti-ZIKV microneutralization tests (MNTs) adapted from 
Beck et al [32]. Away from infection, as is the case in our study, 
detection of ZIKV neutralizing antibodies provides good evi-
dence of a contact with ZIKV [39, 40] (Supplementary Materials 
and Methods).
ZIKV MNT was systematically performed on the first 235 
samples to evaluate the correlation between ZIKV MIA and 
MNT results and to confirm MIA cutoffs.
ZIKV neutralizing antibodies from the MNT were detected 
in 63 of 65 (96.9%) of samples with an MIA ratio of >2.5, in 26 
of 36 (72.2%) of samples with an MIA ratio between 1.5 and 
2.5, and in 12 of 134 (9%) of samples with an MIA ratio of <1.5. 
A sample was considered positive if its MIA ratio was >2.5 and 
negative for a value <1.5. All samples with an MIA ratio between 
1.5 and 2.5 were tested by MNT and considered positive for 
neutralizing titers >20. MNT was also systematically performed 
where the MIA ratio was <1.5 for anyone who had reported 
an arboviral-like infection in the last 2  years (Supplementary 
Materials 2). Finally, almost a quarter of the samples (22.5%; 
n = 607) were also tested by anti-ZIKV MNTs.
Statistical Analysis
We use the following notation to describe the study design 
(Table 1):
Table 1.  Description of the Household Selection Process and Weighted Seroprevalence Estimated by Municipality
Municipality and  
Submunicipality Population No. of Households
No. of Selected 
Households
No. (%) of En-
rolled Households
No. of Enrolled 
Individuals
Weighted Seropreva-
lence, % (95% CI)
Cayenne 57 614 21 659 210 196 (0.9) 446 25.2 (20.2–30.9)
Matoury 32 427 10 778 180 136 (1.3) 265 22.7 (16.5–30.5)
Saint-Laurent 43 600 9770 180 170 (1.7) 301 32.4 (25.7–39.9)
Kourou 26 221 8205 180 167 (2.0) 294 30.1 (23.8–37.3)
Rémire-Montjoly 23 976 8117 120 105 (1.3) 192 13.7 (8.5–20.9)
Macouria 11 719 4218 80 75 (1.8) 164 10.9 (6.8–17.1)
Mana 10 241 2297 80 74 (3.2) 96 16.7 (10.6–25.4)
Maripasoula 11 856 1955 80 74 (3.8) 145 26.7 (16.6–40.0)
 Maripasoula center area … … 55 50 77 45.6 (30.0–62.0)
 Twenke-Talhuen village … … 15 14 33 8.4 (2.6–24.0)
 Antecume-Pata village … … 10 10 35 0 
Apatou 8431 1839 50 45 (2.5) 62 19.1 (10.2–32.9)
Grand-Santi 6969 1447 30 28 (1.9) 61 17.1 (8.3–32.0)
Saint-Georges 4020 1208 40 32 (2.7) 86 27.6 (13.6–47.9)
Papaïchton 7266 1150 40 32 (2.8) 49 22.7 (11.1–40.8)
Sinnamary 2957 1092 30 30 (2.8) 39 37.4 (24.0–53.1)
Roura 3713 983 50 39 (4.0) 70 18.7 (9.7–32.9)
 Roura main area … … 30 26 45 13.7 (5.1–31.7)
 Cacao village … … 20 13 25 27.3 (12.2–50.4)
Montsinéry-Tonnégrande 2473 898 30 29 (3.2) 66 10.7 (2.7–33.9)
Iracoubo 1878 585 30 29 (5.0) 53 10.7 (4.8–22.1)
Régina 946 401 50 43 (10.7) 75 12.0 (5.8–23.4)
 Régina main area … … 40 33 64 13.1 (5.9–26.3)
 Kaw village … … 10 10 11 5.9 (.8–34.0)
Camopi 1769 346 50 50 (14.5) 115 3.7 (1.3–9.8)
 Camopi main area … … 34 34 83 5.3 (2.0–13.5)
 Trois-Sauts village … … 16 16 32 0
Awala 1379 330 30 28 (8.5) 60 25.5 (10.2–50.7)
Saint-Elie 95 143 20 10 (7.0) 11 0
Ouanary 165 140 20 5 (3.6) 13 11.3 (3.0–34.5)
Saül 150 94 20 18 (19.2) 34 2.1 (.3–15.3)
Total 259 865 77 655 1600 1415 2697 23.3 (20.9–25.9)
Abbreviation: CI, confidence interval.
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 • i: one of the 22 strata (municipalities)
 •  Mi: number of primary sampling units (households) 
in the ith stratum, i = 1, …, 22
 •  Si: number of primary sampling units (households) 
selected from the ith stratum, i = 1, …, 22
 •  mi: number of primary sampling units (households) 
actually enrolled from the ith stratum, i = 1, …, 22
 •  Pi: number of individuals living within the i
th stratum, 
i = 1, …, 22 (census data)
 •  pi: number of individuals actually enrolled in the i
th 
stratum, i = 1, …, 22
We considered, that, in each municipality i, the probability of 
selecting a particular subject was equal to the probability to se-
lect his or her household and was (mi/Mi), corresponding to a 
statistical weight equal to (1/ mi/Mi)  = (Mi/mi). This statistical 
weight indicates the number of people in the population repre-
sented by each subject in the sample.
We applied a poststratification adjustment to each of these 
weights to arrive at the final statistical weight for each subject. 
This adjustment allowed us to weight the age-sex groups within 
each municipality to match the distribution in the French 
Guiana total population. Ten age groups (2–4, 5–9, 10–14, 
15–19, 20–24, 25–34, 35–44, 45–54, 55–64 ≥65  years) were 
used within male and female groups, and for each age-sex sub-
group, we applied an adjustment factor cijk, to have a final statis-
tical weight wijk = (Mi/mi) × cijk, where i indexes municipalities, j 
indexes sex groups, and k indexes age groups.
We constructed a household socioeconomic index com-
bining a multiple correspondence analysis and a hierarchical 
cluster analysis (Supplementary Materials and Methods). Type 
of housing, housing equipment such as access to drinking water 
and electricity, presence of a garden, private swimming pool, re-
frigerator, air conditioning, internet access, mobile phone, car, 
boat, type of health insurance, household income, and highest 
educational level were included to determine and characterize 
the natural groupings of households regarding socioeconomic 
levels.
The outcome of interest was the weighted ZIKV seroprev-
alence estimate, and the associated factors were identified by 
using a survey-weighted Poisson regression and prevalence 
ratios (PRs). Any variable having a significant univariate test 
with a P value cutoff point of 0.25 was selected as a candi-
date for the multivariate analysis. The strength of the associ-
ation between selected variables and ZIKV seropositivity was 
estimated by crude and adjusted PRs with their 95% confi-
dence interval (CI), all PRs excluding 1.0 being considered 
as significant.
Analyses were carried out using survey capabilities of Stata 
version 15 statistical software [41] and SPAD 8 [42]. Spatial ana-
lyses were performed using QGIS software [43].
RESULTS
In total, 1415 households and 2697 individuals were in-
cluded from the 27 recruitment areas (Table 1). The mean 
household size was 1.9 individuals (range, 1–11). The mean 
age was 34.1  years (range, 2–75  years). Comparison of the 
sociodemographic characteristics of the study sample to the 
census data demonstrated an overrepresentation of women 
(58.9% vs 50% in the general population of French Guiana) and 
adults >25 years of age (64% vs 53% in French Guiana). These 
differences were accounted for in the analyses of seroprevalence 
and risk factors by allocating poststratification weight to each 
participant.
The crude proportion seropositive was 21.6% and the 
overall weighted seroprevalence of ZIKV antibodies in 
French Guiana was 23.3% (95% CI, 20.9%–25.9%) (Table 1). 
The seroprevalence did not differ according to sex (P =  .65) 
or age (P = .47) (Table 2). Serological results in the different 
geographical areas are shown in Figure 2. While ZIKV cir-
culated in a large part of French Guiana, it barely reached 
the interior and remote villages located in the most isolated 
forest areas (Saint-Elie, Saül, Talhuen-Twenke villages, and 
Camopi) (Table 1). Elevated probabilities of infection were 
observed in the main population centers in Maroni river 
(Maripasoula main area: 45.6% [95% CI, 30.0%–62.0%]; 
Saint-Laurent: 32.4% [95% CI, 25.7%–39.9%]), in the coastal 
area (Kourou: 30.1% [95% CI, 23.8%–37.3%]; Cayenne: 
25.2% [95% CI, 20.2%–30.9%]), and in Low-Oyapock (Saint-
Georges: 27.6% [95% CI, 13.6%–47.9%]). Two smaller geo-
graphical areas in the coastal area were also strongly impacted 
(Sinnamary: 37.4% [95% CI, 24.0%–53.1%]; Cacao: 27.3% 
[95% CI, 12.2%–50.4%]). Living in the northwestern part 
of the territory, so-called “Low Maroni,” in urban areas and 
being born in Haiti was significantly associated with being se-
ropositive in both univariate and multivariate analyses (Table 
2). Living in a carbet, representing a typical Native American 
cabin without walls essentially located in the Amazonian 
forest complex in High Oyapock, interior, and high Maroni 
villages, was significantly associated with being ZIKV sero-
negative at univariate level. The seroprevalence estimated in 
makeshift houses was higher than in individual or collective 
type of housing. However, this difference was not significant, 
probably due to small numbers of individuals in this category. 
Benefiting from universal health coverage or state medical as-
sistance and having a low household income was associated 
with being seropositive at the univariate level. However, soci-
oeconomic factors and type of housing were no longer signif-
icant after adjusting by geographical regions.
The proportion of reported symptoms was estimated at 25.5% 
(95% CI, 20.3%–31.4%) in ZIKV-positive participants vs 3.6% 
(95% CI, 2.6%–5.0%) in seronegative individuals, resulting in a 
ZIKV-attributable symptomatic infection rate of 21.9%.
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Table 2. Factors Associated With Zika Virus Seropositivity
Characteristic Total No. of Tested Individuals
Weighted Prevalence, % 
(95% CI) Crude PR (95% CI) Pearson P Value
Adjusted PR  
(95% CI)
Sex     …
 Male 1108 22.8 (19.6–26.5) Ref .65  
 Female 1589 23.8 (21.0–26.8) 1.04 (.87–1.24)   
Age, y     …
 2–4 63 27.0 (15.2–43.3) Ref .47  
 5–14 494 24.1 (19.1–30.1) .89 (.50–1.59)   
 15–24 413 25.9 (21.0–31.6) .96 (.56–1.66)   
 25–34 471 23.6 (19.2–28.7) .87 (.51–1.50)   
 35–44 442 19.7 (15.8–24.3) .73 (.43–1.25)   
 45–54 362 21.2 (16.5–26.8) .78 (.44–1.39)   
 55–64 284 18.9 (14.3–24.6) .70 (.39–1.27)   
 ≥65 168 28.3 (20.4–37.7) 1.05 (.56–1.95)   
Region of residence      
 Coastal area 1820 22.2 (19.4–25.3) Ref .06 Ref
 Low Maroni 424 28.8 (23.4–34.8) 1.29 (1.02–1.64)  1.41 (1.02–1.95)
 High Maroni 194 25.5 (17.2–36.0) 1.15 (.78–1.70)  1.51 (.91–2.50)
 Low Oyapock 99 27.0 (13.5–46.8) 1.21 (.64–2.32)  1.77 (.89–3.52)
 High Oyapock 115 3.7 (1.3–9.8) .16 (.61–.46)  .26 (.94–.75)
 Interior 45 1.0 (.1–6.9) .04 (.01–.33)  .07 (.01–.52)
Type of housing     …
 Building/collective 365 21.5 (16.4–27.6) Ref .05  
 Individual 1768 23.8 (20.8–27.2) 1.11 (.83–1.49)   
 Carbet 213 5.9 (1.6–18.9) .27 (.08–.97)   
 Makeshift 89 28.3 (17.7–42.1) 1.32 (.79–2.19)   
Type of zone      
 Rural 1304 19.4 (16.2–23.1) Ref .03 Ref
 Urban 1393 24.8 (21.7–28.1) 1.28 (1.02–1.58)  1.45 (1.11–1.91)
Birth place      
 French Guiana 1481 23.4 (20.2–27.1) Ref <10–2 Ref
 Suriname 213 27.0 (20.2–35.1) 1.15 (.85–1.57)  1.08 (.75–1.56)
 Brazil 174 19.1 (13.3–26.7) .82 (.56–1.19)  .82 (.55–1.22)
 Other South America 63 27.6 (17.7–40.3) 1.18 (.77–1.80)  1.18 (.74–1.88)
 Haiti 223 34.3 (20.6–42.3) 1.46 (1.14–1.88)  1.45 (1.08–1.94)
 Caribbean island 136 20.6 (13.5–30.2) .88 (.58–1.34)  .82 (.51–1.31)
 Europe 349 17.0 (12.4–22.8) .72 (.52–1.01)  .76 (.54–1.08)
 Asia 28 4.6 (1.08–17.6) .20 (.04–.82)  .23 (.05–1.14)
 Africa 22 12.4 (3.1–38.6) .53 (.14–1.97)  .56 (.15–2.15)
 Others 8 6.1 (.7–36.6) .26 (.03–2.04)  .32 (.04–2.50)
Household size     …
 1–2 536 20.0 (16.2–24.5) Ref .41  
 3–5 1359 24.1 (20.7–27.8) 1.20 (.93–1.55)   
 ≥6 592 24.6 (18.8–31.6) 1.23 (.88–1.72)   
Household income, €      
 <1000 565 26.9 (22.2–32.1) Ref .10 Ref
 1000–2999 833 24.5 (19.7–29.9) .83 (.48–1.41)  .92 (.67–1.25)
 3000–4999 285 17.7 (12.5–24.3) .53 (.33–.86)  .72 (.46–1.12)
 ≥5000 153 15.7 (9.4–24.9) .48 (.24–.94)  .66 (.37–1.16)
 Not documented 861 24.0 (19.8–28.8) .78 (.56–1.10)  .87 (.62–1.22)
Socioeconomic index      
 Low 233 16.3 (10.8–23.9) Ref .06 Ref
 Intermediate 908 26.5 (21.8–31.8) 1.63 (1.04–2.53)  1.48 (.96–2.26)
 Elevated 1291 21.4 (18.3–24.9) 1.31 (.85–2.02)  1.59 (.97–2.59)
Health insurance status     …
 General social coverage 1330 20.2 (17.3–23.5) Ref <10–2  
 Universal health coverage 1233 25.4 (21.5–29.7) 1.26 (1.00–1.57)   
 State medical assistance 128 36.9 (27.6–47.2) 1.83 (1.34–2.49)   
 No healthcare 6 20.1 (2.5–70.8) .99 (.16–6.94)   
Abbreviations: CI, confidence interval; PR, prevalence ratio.



























































Figure 2. Spatial distribution of Zika virus seroprevalence, French Guiana.
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This proportion varied substantially over space from 27.3% in 
the coastal area to only 12.8% in the High Maroni area, but did 
not vary significantly by sex (28.6% in ZIKV-positive women vs 
21.8% in ZIKV-positive men; P = .22). More than 95% of infected 
individuals who reported the occurrence of a presumptive ZIKV 
infection reported a year of occurrence between 2015 and 2017, 
corresponding to the period of transmission of ZIKV in French 
Guiana. Three-quarters of them (75.8%) declared that diagnosis 
was confirmed by a clinician and 54.7% declared that they had a 
laboratory confirmation. Fever (80.5%) and myalgia (62.4%) were 
the most frequently reported symptoms in ZIKV-positive partici-
pants. However, only rash (38.0%) and arthralgia (33.9%) were sig-
nificantly more prevalent in ZIKV-positive individuals (Table 3).
DISCUSSION
Here we have presented a large-scale representative ZIKV sero-
prevalence study in South America from the recent 2015–2016 
Zika epidemic. We found that approximately a quarter of the 
population of French Guiana became infected during the out-
break. However, there was substantial heterogeneity in infec-
tion risk, with communities in the center of the territory hardly 
affected at all, whereas up to half of the population was infected 
in urban communities along the coast. Our results were con-
sistent with a recent report from a systematic monitoring of 
pregnant women in French Guiana that estimated at 19% the 
proportion of ZIKV-positive women during the first 4 months 
of the outbreak [25].
Our seroprevalence estimates are slightly lower than most 
previous estimates from seroprevalence studies in other loca-
tions in South America [24–28] and in other parts of the world 
[2, 34].This highlights the importance of conducting population-
representative studies. The previous studies in South America have 
all consisted of single communities or small numbers of neigh-
boring populations. Therefore, it has not been possible to gener-
alize the findings to the wider country as is the case here, where 
the entire territory was included in the initial sampling frame. 
The future risk of ZIKV in the area remains unclear. It has been 
shown in a study conducted in Thailand that ZIKV can transi-
tion to stable endemic circulation [44]. Our findings demonstrate 
that the majority of the population remains susceptible to ZIKV, 
which would potentially allow future successful reintroductions 
of the virus. However, the observed differences in seropositivity 
across the country may partly reflect differences in the distribu-
tion of mosquitoes across the territory. Population movements, 
economic development, and urbanization have facilitated the ge-
ographical expansion of Ae. aegypti and its implantation in almost 
all inhabited areas of French Guiana, even in villages along the 
Maroni river up to the Maripasoula main area and inland up to 
Saül [45, 46]. However, to date no study has reported the presence 
of Ae. aegypti populations in the most remote villages including 
Antecume Pata, Twenke-Talhuen, and Camopi [46], where se-
roprevalence rates varied from 0% to 8%. Furthermore, despite 
strengthening existing epidemiological surveillance systems [47] 
and entomo-epidemiological investigations coordinated by local 
health authorities when a clinical or confirmed case appeared in 
these areas, no autochthonous transmission of Aedes-transmitted 
diseases has been identified in these villages.
Differences in vector control activities implemented in 
the different geographical areas may also have contributed 
to variability in transmission intensities between municipal-
ities. Indeed, the French Guiana program of surveillance and 
management of arboviral diseases includes Ae. aegypti den-
sity reduction throughout the year, which is intensified during 
outbreaks. Vector control activities include both indoor and 
outdoor spatial spraying of deltamethrin against adults and 
the removal of breeding sites or their treatment with Bacillus 
thuringiensis var. israelensis–based larvicides [48]. These activ-
ities rely on important logistical and human resources that can 
be in some situations very difficult to apply uniformly in the 
different geographical areas of French Guiana.
We found that individuals with higher income and bene-
fiting from general health insurance had a reduced risk of in-
fection compared to those with lower income and benefiting 
from universal health or state medical assistance in the univar-
iate risk factor analysis. However, after correcting for spatial 
differences in risk, no individual or household-level factor was 
associated with being seropositive. This suggests that the indi-
vidual risk of infection is more deeply modulated by different 
ecoenvironments related to geographic factors, urbanization 
level, and the related quality of sanitary infrastructures that may 
have an impact on the extent of vector infestation and, hence, 
viral circulation.
Table 3. Clinical Symptoms Reported, by Zika Virus Infection Status
Clinical Symptoms
Total (N = 147) ZIKV-Positive Individuals (n = 96) ZIKV-Negative Individuals (n = 51)
Pearson P ValueNo. (%) No. (%) No. (%)
Fever 118 (81.4) 77 (80.5) 41 (83.0) .98
Arthralgia 84 (52.2) 62 (33.9) 22 (61.9) .01
Myalgia 93 (63.1) 61 (62.4) 32 (64.2) .92
Rash 52 (30.1) 41 (38.0) 11 (15.3) .01
Conjunctival hyperemia 28 (18.0) 22 (21.9) 6 (10.6) .10
Abbreviation: ZIKV, Zika virus.
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Whereas the proportion of asymptomatic ZIKV infection in 
ZIKV-positive participants was estimated in previous general 
population cross-sectional studies at 43% in French Polynesia 
[34], 47% in Puerto Rico [49], and 62% in Yap, Micronesia [2], 
we found that 74.5% (95% CI, 68.5%–79.8%) of the participants 
with ZIKV IgG did not report symptoms confirming the high 
proportion of asymptomatic ZIKV infection. Considering that 
the survey was conducted 8 months after the end of the ZIKV 
epidemic in French Guiana, recall bias may nonetheless have led 
to underreporting of symptoms, particularly when there was a 
considerable time delay between the symptoms’ occurrence and 
the time of the survey. Furthermore, even if numerous education 
campaigns may have considerably increased public awareness of 
health risks related to arboviruses in a large majority of the pop-
ulation, awareness about Zika; cultural, social, and behavioral 
practices; or previous expositions to diseases and parasites may 
have affected the reporting of presumptive ZIKV infection.
Our study has other limitations inherent to the study design 
and cross-reaction issues in the context of co-circulation of re-
lated arboviruses.
First, given that individuals without health coverage could not 
be enrolled in our survey because of restrictions from French 
legislation, immigrants without health coverage were underrep-
resented in our sample. Although this population was very small 
in the majority of the municipalities, some households were ex-
cluded in the western border part of the territory, which is known 
for high levels of immigration, because the adults and household 
referents did not have health insurance status. Second, sample 
size calculation was determined to obtain a sufficient point es-
timate of prevalence but not to study risk factors of infection so 
that we might lack power to ascertain them. Finally, cross-reac-
tion between viruses of the same family could have affected the 
interpretation of seroprevalence results. In particular, dengue 
has circulated in French Guiana for decades. Here we used an 
assay that minimizes the risk of cross-reaction by relying on 
the E3 domain of the ZIKV in combination with virus neutral-
ization assay (MNT).We estimated that 9% of those with lower 
MIA values were still seropositive. This means that the true pro-
portion seropositive may be slightly higher than our estimates; 
however, as 76.4% of samples had low MIA results, this would 
only raise the proportion seropositive from 23.3% to 27.1%.
In conclusion, this study is the first to provide a consistent 
overview of a territory-wide ZIKV seropositivity estimation 
in the Americas. Given that a huge proportion of ZIKV infec-
tions are clinically asymptomatic and that the disease is greatly 
underreported, our results provide distinctive and useful in-
formation per geographical area and population subgroups in a 
continental area frequently exposed to arbovirus.
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